SKYEPHARMA PLC - FlutiformTM U.S. NDA Update

SKYEPHARMA PLC -  FlutiformTM U.S. NDA Update

LONDON, UK, 24 June 2010 - SkyePharma PLC (LSE: SKP) announces the outcome of a meeting with the U.S. Food and Drug Administration (FDA) to discuss the Complete Response Letter received in January 2010 in respect of the New Drug Application (NDA) for FlutiformTM (fluticasone propionate/formoterol fumarate), an investigational treatment for persistent asthma in patients 12 years of age and older.

As previously disclosed, in the Complete Response Letter the FDA stated that it could not approve the NDA in its present form and raised a number of new substantive issues to be addressed, which, if undertaken, would involve significant additional clinical work including generating additional data on dose ranging.

From the discussions held at the meeting it is apparent that the FDA's requirements for approving FlutiformTM have changed materially during the course of the development program, and meeting these requirements would involve significant additional work, including a large post-approval safety study.

The Company is working with its advisers to review all of the options available to it with a view to determining whether there is a viable way forward for FlutiformTM in the United States.

 

In the meantime the European Marketing Authorisation Application for FlutiformTM, filed in March 2010, remains under regulatory review in Europe, where the regulatory approach is different from the United States, and progress continues to be made with the development in Japan.

 

For further information please contact:

 

SkyePharma PLC
 
 
 
 
 
Ken Cunningham, Chief Executive Officer
 +44 207 491 1777
 
Peter Grant, Chief Financial Officer
  

Financial Dynamics
 
 
Jonathan Birt /Sue Quigley
 +44 207 831 3113
 

About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops new formulations of known molecules to provide a clinical advantage and life-cycle extension.  The Group has twelve approved products in the areas of oral, inhalation and topical delivery.  The Group's products are marketed throughout the world by leading pharmaceutical companies.  For more information, visit www.skyepharma.com.

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.